|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside显示文摘MicroRNAs(miRNAs) are small, single-stranded, noncoding RNAs that can post-transcriptionally regulate the expression of various oncogenes and tumor suppressor genes. Dysregulated expression of many miRNAs have been shown to mediate the signaling pathways critical in the multistep carcinogenesis of colorectal cancer(CRC). MiR NAs are stable and protected from RNase-mediated degradation, thereby enabling its detection in biological fluids and archival tissues for biomarker studies. This review focuses on the role and application of miRNAs in the prognosis and therapy of CRC. While stage Ⅱ CRC is potentially curable by surgical resection, a significant percentage of stage Ⅱ CRC patients do develop recurrence. MiRNA biomarkers may be used to stratify such high-risk population for adjuvant chemotherapy to provide better prognoses. Growing evidence also suggests that miRNAs are involved in the metastatic process of CRC. Certain of these miRNAs may thus be used as prognostic biomarkers to identify patients more likely to have micro-metastasis, who could be monitored more closely after surgery and/or given more aggressive adjuvant chemotherapy. Intrinsic and acquired resistance to chemotherapy severely hinders successful chemotherapy in CRC treatment. Predictive miRNA biomarkers for response to chemotherapy may identify patients who will benefit the most from a particular regimen and also spare the patients from unnecessary side effects. Selection of patients to receive the new targeted therapy is becoming possible with the use of predictive miRNA biomarkers. Lastly, forced expression of tumor suppressor miRNA or silencing of oncogenic miRNA in tumors by gene therapy can also be adopted to treat CRC alone or in combination with other chemotherapeutic drugs. | Kenneth KW To Christy WS Tong Mingxia Wu William CS Cho | 2018 | World Journal of Gastroenterology2018，24，27： | 29 |
| 2 | High-intensity focused ultrasound ablation:An effective bridging therapy for hepatocellular carcinoma patients显示文摘AIM:To analyze whether high-intensity focused ultrasound(HIFU) ablation is an effective bridging therapy for patients with hepatocellular carcinoma(HCC).METHODS:From January 2007 to December 2010,49 consecutive HCC patients were listed for liver transplantation(UCSF criteria).The median waiting time for transplantation was 9.5 mo.Twenty-nine patients received transarterial chemoembolization(TACE) as a bringing therapy and 16 patients received no treatment before transplantation.Five patients received HIFU ablation as a bridging therapy.Another five patients with the same tumor staging(within the UCSF criteria) who received HIFU ablation but not on the transplant list were included for comparison.Patients were comparable in terms of Child-Pugh and model for end-stage liver disease scores,tumor size and number,and cause of cirrhosis.RESULTS:The HIFU group and TACE group showed no difference in terms of tumor size and tumor number.One patient in the HIFU group and no patient in the TACE group had gross ascites.The median hospital stay was 1 d(range,1-21 d) in the TACE group and two days(range,1-9 d) in the HIFU group(P < 0.000).No HIFU-related complication occurred.In the HIFU group,nine patients(90%) had complete response and one patient(10%) had partial response to the treatment.In the TACE group,only one patient(3%) had response to the treatment while 14 patients(48%) had stable disease and 14 patients(48%) had progressive disease(P = 0.00).Seven patients in the TACE group and no patient in the HIFU group dropped out from the transplant waiting list(P = 0.559).CONCLUSION:HIFU ablation is safe and effective in the treatment of HCC for patients with advanced cirrhosis.It may reduce the drop-out rate of liver transplant candidate. | Tan To Cheung Sheung Tat Fan See Ching Chan Kenneth SH Chok Ferdinand SK Chu Caroline R Jenkins Regina CL Lo James YY Fung Albert CY Chan William W Sharr Simon HY Tsang Wing Chiu Dai Ronnie TP Poon Chung Mau Lo | 2013 | World Journal of Gastroenterology2013，19，20： | 23 |
| 3 | SPIRIT 2013声明:定义临床研究方案的标准条目显示文摘临床研究方案是临床研究设计、实行、报告和评价的基础。然而,临床研究方案及现存的临床研究方案指引在内容和质量上差异很大。本文描述了《规范临床研究方案内容》(Standard Protocol Items:Recommendations for Interventional Trials 2013 ),简称SPIRIT2013声明,一个临床研究方案必须报告的条目指引的系统建立和范围。 | An-Wen Chan Jennifer M.Tetzlaff Douglas G.Altman Andreas Laupacis Peter C.GΦtzsche Karmela Krleza-Jeri AsbjΦrn Hróbjartsson Howard Mann Kay Dickersin Jesse A.Berlin Caroline J.Doré Wendy R.Parulekar William S.M.Summerskill Trish Groves Kenneth F.Schulz Harold C.Sox Frank W.Rockhold Drummond Rennie David Moher 钟丽丹 郑颂华 吴泰相 李幼平 商洪才 张伯礼 唐旭东 吕爱平 卞兆祥 | 2013 | 中国循证医学杂志2013，13，12： | 23 |
| 4 | Neuroendocrine tumors of the gastrointestinal tract: Case reports and literature review显示文摘Neuroendocrine tumors(NET)previously called carcinoid tumors are neoplasms of enterochromaffin/neuroendocrine cell origin which display neurosecretory capacity that may result in the carcinoid syndrome.The annual incidence of patients with NET is 8.4 per 100000;yet many NET remain asymptomatic and clinically undetected.A majority of NET follows a benign course;however,some will display malignant characteristics.NET most commonly occur in the gastrointestinal tract(67%)and bronchopulmonary system(25%).Gastrointestinal NET occur within the stomach,small intestine,liver,and rectum.We report a retrospective study of 11 subjects:Eight with benign carcinoid tumors:duodenal bulb(n=2),terminal ileum(n=1),sigmoid colon(n=2),and rectum(n=3);three with malignant carcinoid:liver(n=1)and intra-abdominal site(n=2).The diagnosis,endoscopic images,outcome,treatment and review of the literature are presented. | William J Salyers Kenneth J Vega Juan Carlos Munoz Bruce W Trotman Silvio S Tanev | 2014 | World Journal of Gastrointestinal Oncology2014，6，8： | 8 |
| 5 | Next-Generation Stool DNA Test Accurately Detects Colorectal Cancer and Large Adenomas显示文摘 | David A. Ahlquist Hongzhi Zou Michael Domanico Douglas W. Mahoney Tracy C. Yab William R. Taylor Malinda L. Butz Stephen N. Thibodeau Linda Rabeneck Lawrence F. Paszat Kenneth W. Kinzler Bert Vogelstein Niels Chr. Bjerregaard S?ren Laurberg Henrik Toft S? | 2012 | Gastroenterology2012，，2： | 7 |
| 6 | TIMI Frame Count: A Quantitative Method of Assessing Coronary Artery Flow显示文摘 | C. Michael Gibson Christopher P. Cannon William L. Daley Jr Dodge Barbara Alexander Susan J. Marble Carolyn H. McCabe Lori Raymond Terry Fortin W. Kenneth Poole Eugene Braunwald | 1996 | Circulation1996，，5： | 6 |
| 7 | Modulation of graft vascular inflow guided by flowmetry and manometry in liver transplantation显示文摘BACKGROUND:Survival of the partial graft after living donor liver transplantation owes much to its tremendous regenerative ability.With excellent venous outflow capacity,a graft within a wide range of graft-to-standard-liver-volume ratios can cope with portal hypertension that is common in liver transplant recipients.However,when the ratio range is exceeded,modulation of graft vascular inflow becomes necessary for graft survival.The interplay between graft-to-standard-liver-volume ratio and portal pressure,in the presence of portosystemic shunt or otherwise,requires individualized modulation of graft portal and arterial inflows.Boosting of portal inflow by shunt ligation can be guided by transonic flowmetry,whereas muting of portal inflow by splenic artery ligation can be monitored by portal electronic manometry.METHOD:We describe four cases to illustrate the above.RESULTS:One patient had hepatic artery thrombosis resulting from splenic artery steal syndrome which was the sequela of small-for-size syndrome.Emergency splenic artery ligation and re-anastomosis of the hepatic artery successfully muted the portal inflow and boosted the hepatic arterial inflow.Another patient with portal vein thrombosis underwent thrombendvenectomy.Portal inflow was boosted with ligation of portosystemic shunt,which is often present in these patients with portal hypertension.The coexistence of splenic aneurysm and splenorenal shunt required ligation of both in the third patient.The fourth patient,with portal pressure and flow monitoring,avoided ligation of a coronary vein which became a main portal inflow after portal thrombendvenectomy.CONCLUSION:Management of graft inflow modulation guided selectively by transonic flowmetry or portal manometry was described. | See Ching Chan Chung Mau Lo Kenneth SH Chok William W Sharr Tan To Cheung Simon HY Tsang Albert CY Chan Sheung Tat Fan | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，6： | 5 |
| 8 | Discovery of high-entropy ceramics via machine learning显示文摘Although high-entropy materials are attracting considerable interest due to a combination of useful properties and promising applications,predicting their formation remains a hindrance for rational discovery of new systems.Experimental approaches are based on physical intuition and/or expensive trial and error strategies.Most computational methods rely on the availability of sufficient experimental data and computational power.Machine learning(ML)applied to materials science can accelerate development and reduce costs.In this study,we propose an ML method,leveraging thermodynamic and compositional attributes of a given material for predicting the synthesizability(i.e.,entropy-forming ability)of disordered metal carbides. | Kevin Kaufmann Daniel Maryanovsky William M.Mellor Chaoyi Zhu Alexander S.Rosengarten Tyler J.Harrington Corey Oses Cormac Toher Stefano Curtarolo Kenneth S.Vecchio | 2020 | npj Computational Materials2020，，1： | 5 |
| 9 | Stem cell therapy for the treatment of Leydig cell dysfunction in primary hypogonadism显示文摘The production of testosterone occurs within the Leydig cells of the testes. When production fails at this level from either congenital, acquired, or systemic disorders,the result is primary hypogonadism. While numerous testosterone formulations have been developed, none are yet fully capable of replicating the physiological patterns of testosterone secretion. Multiple stem cell therapies to restore androgenic function of the testes are under investigation. Leydig cells derived from bone marrow, adipose tissue, umbilical cord, and the testes have shown promise for future therapy for primary hypogonadism. In particular, the discovery and utilization of a group of progenitor stem cells within the testes, known as stem Leydig cells(SLCs), has led not only to a better understanding of testicular development, but of treatment as well. When combining this with an understanding of the mechanisms that lead to Leydig cell dysfunction, researchers and physicians will be able to develop stem cell therapies that target the specific step in the steroidogenic process that is deficient. The current preclinical studies highlight the complex nature of regenerating this steroidogenic process and the problems remain unresolved. In summary, there appears to be two current directions for stem cell therapy in male primary hypogonadism. The first method involves differentiating adult Leydig cells from stem cells of various origins from bone marrow, adipose, or embryonic sources. The second method involves isolating, identifying, and transplanting stem Leydig cells into testicular tissue. Theoretically, in-vivo re-activation of SLCs in men with primary hypogonadism due to age would be another alternative method to treat hypogonadism while eliminating the need for transplantation. | Taylor C Peak Nora M Haney William Wang Kenneth J DeLay Wayne J Hellstrom | 2016 | World Journal of Stem Cells2016，8，10： | 5 |
| 10 | Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation显示文摘 | James Fung Cindy Cheung See–Ching Chan Man–Fung Yuen Kenneth S.H. Chok William Sharr Wing–Chiu Dai Albert C.Y. Chan Tan–To Cheung Simon Tsang Banny Lam Ching–Lung Lai Chung–Mau Lo | 2011 | Gastroenterology2011，，4： | 3 |
| 11 | Clinical factors affecting rejection rates in liver transplantation显示文摘BACKGROUND: With improvements in survival, liver transplant recipients now suffer more morbidity from long-term immunosuppression. Considerations were given to develop individualized immunosuppression based on their risk of rejection. METHOD: We retrospectively analyzed the data of 788 liver transplants performed during the period from October 1991 to December 2011 to study the relationship between acute cellular rejection(ACR) and various clinical factors. RESULTS: Multivariate analysis showed that older age(P=0.04,OR=0.982), chronic hepatitis B virus infection(P=0.005, OR=0.574), living donor liver transplantation(P=0.02, OR=0.648) and use of interleukin-2 receptor antagonist on induction(P<0.001, OR=0.401) were associated with fewer ACRs. Patients with fulminant liver failure(P=0.004, OR=4.05) were more likely to develop moderate to severe grade ACR. CONCLUSIONS: Liver transplant recipients with older age,chronic hepatitis B virus infection, living donor liver transplantation and use of interleukin-2 receptor antagonist on induction have fewer ACR. Patients transplanted for fulminant liver failure are at higher risk of moderate to severe grade ACR.These results provide theoretical framework for developing individualized immunosuppression. | Kin Pan Au See-Ching Chan Kenneth Siu-Ho Chok William Wei Sharr Wing-Chiu Dai Sui-Ling Sin Tiffany Cho-Lam Wong Chung-Mau Lo | 2015 | Hepatobiliary & Pancreatic Diseases International2015，14，4： | 3 |
| 12 | Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement显示文摘 | Mark P. Callery MD Kenneth J. Chang MD Elliot K. Fishman MD Mark S. Talamonti MD L. William Traverso MD David C. Linehan MD | 2009 | Annals of Surgical Oncology2009，，7： | 3 |
| 13 | Outcomes after percutaneous reduction and fixation of proximal humeral fractures显示文摘 | Jay D. Keener Brad O. Parsons Evan L. Flatow Kenneth Rogers Gerald R. Williams Leesa M. Galatz | 2007 | Journal of Shoulder and Elbow Surgery2007，，3： | 3 |
| 14 | Overview of the J-TEXT progress on RMP and disruption physics显示文摘The J-TEX T tokam ak has been operated for ten years since its first plasm a obtained at the end of 2007. The diagnostics development and main modulation systems, i.e. resonant magnetic perturbation(RMP) system s and m assive gas injection(MGI) systems, will be introduced in this paper. Supported by these efforts, J-TEX T has contributed to research on several topics, especially on RMP physics and disruption m itigation. Both experim ental and theoretical research show that RMP could lock, suppress or excite the tearing modes, depending on the RMP am plitude, frequency difference between RMP and rational surface rotation, and initial stabilities. The plasm a rotation, particle transport and operation region are influenced by the RMP. Utilizing the MGI valves, disruptions have been mitigated with pure He, pure Ne, and a mixture of He and Ar(9:1). A significant runaway current plateau could be generated with m oderate amounts of Ar injection. The RMP has been shown to suppress the generation of runaway current during disruptions. | 丁永华 陈忠勇 陈志鹏 杨州军 王能超 胡启明 饶波 陈杰 程芝峰 丽高 江中和 王璐 王之江 张晓卿 郑玮 张明 庄革 虞清泉 梁云峰 于克训 胡希伟 潘垣 Kenneth William GENTLE J-TEXT Team | 2018 | Plasma Science and Technology2018，20，12： | 3 |
| 15 | High-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients awaiting liver transplantation显示文摘The scarcity of liver grafts in Asia leads to a significant dropout of patients from liver transplant waiting lists, particularly patients with hepatocellular carcinoma and a low model for end-stage liver disease score. In order to reduce dropping out, different bridging therapies are employed. We report the use of high-intensity focused ultrasound ablation as a bridging therapy for a patient with hepatocellular carcinoma of stage two and an extremely low platelet count (20×10 9 /L). The ablation was successful. Blood tests showed that his liver function was similar before and after the treatment. No adhesion was encountered in the liver transplantation performed six months later. | Tan To Cheung Kenneth SH Chok Regina CL Lo William W Sharr See Ching Chan Ronnie TP Poon Sheung Tat Fan Chung Mau Lo | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，5： | 3 |
| 16 | Splenic Artery Aneurysms: Two Decades Experience at Mayo Clinic显示文摘 | Maher A. Abbas William M. Stone Richard J. Fowl Peter Gloviczki W. Andrew Oldenburg Peter C. Pairolero John W. Hallett Thomas C. Bower Jean M. Panneton Kenneth J. Cherry | 2002 | Annals of Vascular Surgery2002，，： | 2 |
| 17 | Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report显示文摘A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC. | Kermit V Speeg William Kenneth Washburn Glenn Halff | 2010 | World Journal of Gastroenterology2010，16，43： | 2 |
| 18 | Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants显示文摘 | George K. Siberry Paige L. Williams Hermann Mendez George R. Seage Denise L. Jacobson Rohan Hazra Kenneth C. Rich Raymond Griner Katherine Tassiopoulos Deborah Kacanek Lynne M. Mofenson Tracie Miller Linda A. DiMeglio D. Heather Watts | 2012 | AIDS2012，，9： | 2 |
| 19 | Effect of particle degradation on electrostatic sensor measurements and flow characteristics in dilute pneumatic conveying显示文摘 | Wei Chen Jianyong Zhang Timothy Donohua Kenneth Williams Ruixue Cheng Mark Jones Bin Zhou | 2017 | Particuology2017，15，4： | 2 |
| 20 | Bile duct anastomotic stricture after adult‐to‐adult right lobe living donor liver transplantation显示文摘 | Kenneth Siu Ho Chok See Ching Chan Tan To Cheung William Wei Sharr Albert Chi Yan Chan Chung Mau Lo Sheung Tat Fan | 2011 | Liver Transpl2011，，1： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员